»ó´Ü¿©¹é
±â»ç (Àüü 393°Ç)
[Hot Discussion] ´ç´¢º´ ¾à¹° ¾Æ¿ôÄÄ °ËÁõ, ½ÅÀå±â´ÉÀ¸·Î È®´ë ÀÓ¼¼Çü ±âÀÚ 2016-11-14 18:36
[Deep in Guideline] 2016 AACE/ACE ´ç´¢º´ Á¾ÇÕ°ü¸® °¡À̵å¶óÀÎ ÀÌ»óµ· ±âÀÚ 2016-11-14 17:40
[Sub Story] ARB + CCB °íÇ÷¾Ð °ü¸® ÃÖÀûÀÇ º´¿ë¿ä¹ý ÀÓ¼¼Çü ±âÀÚ 2016-11-09 18:49
[Sub Story] ¾È¹æ¼­ ±¹»ê ARB À§¿ë ¼¼°è¿¡ °ú½Ã ÀÌ»óµ· ±âÀÚ 2016-11-09 18:36
[Sub Story] ÀÓ»ó±Ù°Å·Î ¹«ÀåÇÑ Æ丰µµÇÁ¸± º´¿ë¿ä¹ý ÀÌ»óµ· ±âÀÚ 2016-11-09 18:31
¶óÀÎ
[Hot Discussion] ½É±Ù°æ»öÁõ ȯÀÚ¿¡¼­ RAS¾ïÁ¦Á¦ ¿ªÇÒ ÀÓ¼¼Çü ±âÀÚ 2016-11-09 17:01
[Late Breaking Studies] ÇǸ¶»ìź, ´ë»çÁõÈıº ÀÎÁöµµ °³¼± ÀÌ»óµ· ±âÀÚ 2016-11-09 16:56
[Sub Story] ³ëÀÎ ½ÉÇ÷°üÁúȯ À§ÇèÀÎÀÚ °ü¸® ÀÌ»óµ· ±âÀÚ 2016-10-28 17:42
[Sub Story] Ú¸ °¡À̵å¶óÀÎ ÅëÇØ º» ¿©¼º ½ÉÇ÷°üÁúȯ ¿¹¹æÀü·« ÀÌ»óµ· ±âÀÚ 2016-08-08 13:32
[Deep in Guideline] ¡°½ÉÇ÷°ü»ç°Ç °¨¼Ò¿¡ SGLT-2 ¾ïÁ¦Á¦ °í·Á¡± ÀÌ»óµ· ±âÀÚ 2016-08-08 11:32
¶óÀÎ
[Deep in Guideline] ESC, ½ÉºÎÀü Ä¡·áÀü·«¿¡ ARNI Ãß°¡ ÀÓ¼¼Çü ±âÀÚ 2016-08-08 11:22
[Sub Story] ´ë»çÁõÈıº ȯÀÚ¿¡¼­ ¾à¹° º´ÇÕ¿ä¹ý°ú º¹ÇÕÁ¦¡¤Æú¸®ÇÊ Àü·« ÀÓ¼¼Çü ±âÀÚ 2016-05-18 10:32
[Sub Story] Ç×°íÇ÷¾ÐÁ¦ÀÇ Ç÷¾ÐÁ¶Àý ¹× ½ÉÇ÷°ü º¸È£È¿°ú ÀÓ¼¼Çü ±âÀÚ 2016-05-17 22:10
[Sub Story] Ç×°íÇ÷¾ÐÁ¦ º´ÇÕ¿ä¹ýÀÇ ½ÉÇ÷°ü ÀÓ»óÇýÅà ÀÓ¼¼Çü ±âÀÚ 2016-05-17 21:58
[Sub Story] ½ºÅ¸Æ¾ + ¿¡Á¦Æ¼¹Ìºê Àü·« Pleiotropic Effect of Ezetimibe ÀÌ»óµ· ±âÀÚ 2016-05-17 20:44
¶óÀÎ
[Sub Story] ´ë»çÁõÈıº, Ç÷¾Ð¡¤Ç÷´ç¡¤ÁöÁú Á¾ÇÕÄ¡·á ÀÌ»óµ· ±âÀÚ 2016-05-09 18:21
[Sub Story] ´ë»çÁõÈıº Æú¸®ÇÊ Àü·« ÀÌ»óµ· ±âÀÚ 2016-05-09 18:16
[Interview] ¡°°íÇ÷¾Ð¡¤ÀÌ»óÁöÁúÇ÷Áõ µ¿¹Ý, º¹ÇÕÁ¦·Î ¼øÀÀµµ¡¤½Ã³ÊÁö ±â´ë¡± ÀÓ¼¼Çü ±âÀÚ 2016-04-28 16:39
[Sub Story] Ç×°íÇ÷¾ÐÁ¦ º´¿ë¿ä¹ý ¾ç¡¤Áú ¸ðµÎ¿¡¼­ ÇýÅà ÀÌ»óµ· ±âÀÚ 2016-04-12 16:30
[Conference Report] 2016 ±¹Á¦³úÁ¹ÁßÇмú´ëȸ ÇÏÀ϶óÀÌÆ® ÀÓ¼¼Çü ±âÀÚ 2016-04-12 13:39
Back to Top